{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mismatch+Repair+Deficient+Solid+Malignant+Tumor", "query": { "condition": "Mismatch Repair Deficient Solid Malignant Tumor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mismatch+Repair+Deficient+Solid+Malignant+Tumor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:19:21.299Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT05199272", "title": "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Neuroendocrine Tumors", "MSI-H Cancer", "Cancer With A High Tumor Mutational Burden", "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "23ME-00610", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "23andMe, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 141, "start_date": "2021-12-29", "completion_date": "2025-03", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 10, "location_summary": "Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199272" }, { "nct_id": "NCT04001101", "title": "Anti-PD-1 +/- RT for MSI-H Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Instability High", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "RT and Anti-PD-1", "type": "COMBINATION_PRODUCT" }, { "name": "Anti-PD-1", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 0, "start_date": "2019-10-10", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001101" }, { "nct_id": "NCT06974110", "title": "Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Endometrial Cancer", "MSI-H Cancer", "Colorectal Cancer", "Gastric Cancer", "dMMR Cancer" ], "interventions": [ { "name": "MOMA-341", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Immunotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MOMA Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2025-07-16", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 8, "location_summary": "San Diego, California • Tampa, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974110" }, { "nct_id": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Mutant", "Glioblastoma, IDH-wildtype", "Brain Metastases, Adult", "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Microsatellite Instability-High Solid Malignant Tumor", "Mismatch Repair Deficient Solid Malignant Tumor", "Microsatellite Instability-High Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma", "Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "NEO212 Oral Capsule", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2023-11-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 6, "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047379" }, { "nct_id": "NCT06710847", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Colorectal", "Solid Tumor", "Colon Cancer", "Rectal Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "GSK4418959", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2024-12-13", "completion_date": "2026-06-22", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710847" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT04165772", "title": "Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Clinical Stage: Stage II (T3-4, N-)", "Stage III (Any T, N+)", "Solid Tumor", "Solid Tumor, Adult" ], "interventions": [ { "name": "TSR-042 or Dostarlimab", "type": "DRUG" }, { "name": "capecitabine or 5-FU", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 212, "start_date": "2019-12-11", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165772" }, { "nct_id": "NCT06898450", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors Cancer", "MSI-H Cancer" ], "interventions": [ { "name": "NDI-219216", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Wadjet, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 134, "start_date": "2025-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ithaca", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06898450" }, { "nct_id": "NCT04439214", "title": "Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2016-05-31", "completion_date": "2020-05-17", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-05-21T23:19:21.299Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439214" } ] }